{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:33:40Z","timestamp":1788910420640,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201400006C"],"award-info":[{"award-number":["HHSN272201400006C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015090","name":"Imam Abdulrahman Bin Faisal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007787","name":"National Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000046","name":"National Research Council Canada","doi-asserted-by":"publisher","award":["MP120801"],"award-info":[{"award-number":["MP120801"]}],"id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002349","name":"Academy of Scientific Research and Technology","doi-asserted-by":"publisher","award":["7303"],"award-info":[{"award-number":["7303"]}],"id":[{"id":"10.13039\/501100002349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007615","name":"University of Dammam","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.heliyon.2021.e07962","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:57:44Z","timestamp":1631149064000},"page":"e07962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7691-3656","authenticated-orcid":false,"given":"Amal","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2878-5714","authenticated-orcid":false,"given":"Ahmed","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Al-Karmalawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0045-0354","authenticated-orcid":false,"given":"Ahmad","family":"Zidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamada S.","family":"Abulkhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-9398","authenticated-orcid":false,"given":"Mahmoud","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3896-6911","authenticated-orcid":false,"given":"Mahmoud M.","family":"Elhefnawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10236","key":"10.1016\/j.heliyon.2021.e07962_bib1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.heliyon.2021.e07962_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8070991","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): state of the science","volume":"8","author":"Mostafa","year":"2020","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.heliyon.2021.e07962_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.heliyon.2021.e07962_bib4","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.onehlt.2020.100170","article-title":"One Health in the context of coronavirus outbreaks: a systematic literature review","volume":"10","author":"Schmiege","year":"2020","journal-title":"One Health"},{"key":"10.1016\/j.heliyon.2021.e07962_bib5","doi-asserted-by":"crossref","first-page":"100604","DOI":"10.1016\/j.imu.2021.100604","article-title":"The journey of antimalarial drugs against SARS-CoV-2: review article","author":"Sarhan","year":"2021","journal-title":"Informat. Med. Unlocked"},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s43141-020-00055-5","article-title":"Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?","volume":"18","author":"Mahmoud","year":"2020","journal-title":"J.\u00a0Genet. Engin. Biotechn."},{"issue":"4","key":"10.1016\/j.heliyon.2021.e07962_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.heliyon.2021.e07962_bib8","article-title":"Calendulaglycoside A showing potential activity against SARS-CoV-2 main protease: molecular docking, molecular dynamics, and SAR studies","author":"Zaki","year":"2021","journal-title":"J.\u00a0Tradit. Complem. Med."},{"key":"10.1016\/j.heliyon.2021.e07962_bib9","first-page":"1","article-title":"In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins","author":"Elmaaty","year":"2021","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"issue":"6","key":"10.1016\/j.heliyon.2021.e07962_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/pathogens10060758","article-title":"Bioactive polyphenolic compounds showing strong antiviral activities against severe acute respiratory syndrome coronavirus 2","volume":"10","author":"Kandeil","year":"2021","journal-title":"Pathogens"},{"issue":"5","key":"10.1016\/j.heliyon.2021.e07962_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/pathogens10050623","article-title":"Strong inhibitory activity and action modes of synthetic maslinic acid derivative on highly pathogenic coronaviruses: COVID-19 drug candidate","volume":"10","author":"Soltane","year":"2021","journal-title":"Pathogens"},{"issue":"12","key":"10.1016\/j.heliyon.2021.e07962_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/ph13120443","article-title":"FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2","volume":"13","author":"Mostafa","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.heliyon.2021.e07962_bib13","series-title":"Molecular Docking and Dynamics Simulations Reveal the Potential of Anti-HCV Drugs to Inhibit COVID-19 Main Protease","author":"Al-Karmalawy","year":"2021"},{"issue":"10","key":"10.1016\/j.heliyon.2021.e07962_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug repurposing for viral infectious diseases: how far are we?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol."},{"issue":"2","key":"10.1016\/j.heliyon.2021.e07962_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01914-16","article-title":"Clinically approved ion channel inhibitors close gates for hepatitis C virus and open doors for drug repurposing in infectious viral diseases","volume":"91","author":"Pietschmann","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.heliyon.2021.e07962_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s11030-020-10166-3","article-title":"First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery","author":"Amin","year":"2021","journal-title":"Mol. Divers."},{"issue":"7811","key":"10.1016\/j.heliyon.2021.e07962_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.heliyon.2021.e07962_bib18","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.heliyon.2021.e07962_bib19","doi-asserted-by":"crossref","first-page":"14614","DOI":"10.1128\/JVI.79.23.14614-14621.2005","article-title":"ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia","volume":"79","author":"Jia","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.heliyon.2021.e07962_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bbrc.2021.03.118","article-title":"Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation","volume":"555","author":"Padhi","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2478\/jtim-2020-0003","article-title":"Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management","volume":"8","author":"Liu","year":"2020","journal-title":"J.\u00a0Transl. Int. Med."},{"issue":"227","key":"10.1016\/j.heliyon.2021.e07962_bib22","article-title":"Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor","volume":"9","author":"Al-Karmalawy","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.heliyon.2021.e07962_bib23","doi-asserted-by":"crossref","first-page":"107587","DOI":"10.1016\/j.pharmthera.2020.107587","article-title":"Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients","volume":"213","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.heliyon.2021.e07962_bib24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1021\/acsptsci.0c00113","article-title":"Can SARS-CoV-2 accumulate mutations in the S-protein to increase pathogenicity?","volume":"3","author":"Padhi","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/v13010106","article-title":"Systematic search for SARS-CoV-2 main protease inhibitors for drug repurposing: ethacrynic acid as a potential drug","volume":"13","author":"Isgr\u00f2","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib26","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib27","doi-asserted-by":"crossref","first-page":"101992","DOI":"10.1016\/j.isci.2020.101992","article-title":"High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance","volume":"24","author":"Padhi","year":"2021","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.heliyon.2021.e07962_bib28","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.3390\/molecules26123772","article-title":"Computational insights on the potential of some NSAIDs for treating COVID-19: priority set and lead optimization","volume":"26","author":"Abo Elmaaty","year":"2021","journal-title":"Molecules"},{"issue":"17","key":"10.1016\/j.heliyon.2021.e07962_bib29","doi-asserted-by":"crossref","first-page":"10027","DOI":"10.1039\/D0RA10674G","article-title":"Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study","volume":"11","author":"Elmaaty","year":"2021","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1128\/AAC.00677-09","article-title":"MK-7009, a potent and selective inhibitor of hepatitis C virus NS3\/4A protease","volume":"54","author":"Liverton","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.heliyon.2021.e07962_bib31","first-page":"845","article-title":"The performance of current methods in ligand\u2013protein docking","author":"McConkey","year":"2002","journal-title":"Curr. Sci."},{"issue":"6","key":"10.1016\/j.heliyon.2021.e07962_bib32","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acsptsci.0c00144","article-title":"Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies","volume":"3","author":"Eliaa","year":"2020","journal-title":"ACS Pharmacol. Translat. Sci."},{"key":"10.1016\/j.heliyon.2021.e07962_bib33","first-page":"1","article-title":"Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study","author":"Miroshnychenko","year":"2021","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.heliyon.2021.e07962_bib34","article-title":"Structural similarity of SARS-CoV2 M(pro) and HCV NS3\/4A proteases suggests new approaches for identifying existing drugs useful as COVID-19 therapeutics","author":"Bafna","year":"2020","journal-title":"ChemRxiv"},{"issue":"7","key":"10.1016\/j.heliyon.2021.e07962_bib35","doi-asserted-by":"crossref","first-page":"109133","DOI":"10.1016\/j.celrep.2021.109133","article-title":"Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture","volume":"35","author":"Bafna","year":"2021","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.heliyon.2021.e07962_bib36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.str.2020.10.007","article-title":"Malleability of the SARS-CoV-2 3CL M(pro) active-site cavity facilitates binding of clinical antivirals","volume":"28","author":"Kneller","year":"2020","journal-title":"Structure"},{"key":"10.1016\/j.heliyon.2021.e07962_bib37","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jpcb.1c04556","article-title":"Accelerating COVID-19 research using molecular dynamics simulation","author":"Padhi","year":"2021","journal-title":"J.\u00a0Phys. Chem. B"},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J\u00a0Transl Int Med"},{"issue":"D1","key":"10.1016\/j.heliyon.2021.e07962_bib39","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.heliyon.2021.e07962_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nbt1284","article-title":"Relating protein pharmacology by ligand chemistry","volume":"25","author":"Keiser","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"Web Server issue","key":"10.1016\/j.heliyon.2021.e07962_bib41","doi-asserted-by":"crossref","first-page":"W32","DOI":"10.1093\/nar\/gku293","article-title":"SwissTargetPrediction: a web server for target prediction of bioactive small molecules","volume":"42","author":"Gfeller","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13321-017-0199-x","article-title":"The polypharmacology browser: a web-based multi-fingerprint target prediction tool using ChEMBL bioactivity data","volume":"9","author":"Awale","year":"2017","journal-title":"J.\u00a0Cheminf."},{"key":"10.1016\/j.heliyon.2021.e07962_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr. Protoc. Bioinformat."},{"issue":"18","key":"10.1016\/j.heliyon.2021.e07962_bib44","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802608786786624","article-title":"Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery","volume":"8","author":"Vilar","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.heliyon.2021.e07962_bib45","series-title":"Molecular Operating Environment (MOE)","year":"2016"},{"issue":"40","key":"10.1016\/j.heliyon.2021.e07962_bib46","doi-asserted-by":"crossref","first-page":"17374","DOI":"10.1039\/D0NJ04088F","article-title":"Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K\/AKT\/mTOR pathway and inhibition of topoisomerase II: in vitro and molecular docking studies","volume":"44","author":"Ghanem","year":"2020","journal-title":"New J. Chem."},{"issue":"92","key":"10.1016\/j.heliyon.2021.e07962_bib47","article-title":"Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations","volume":"9","author":"Khattab","year":"2021","journal-title":"Front. Chem."},{"issue":"7807","key":"10.1016\/j.heliyon.2021.e07962_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2021.e07962_bib49","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.sajb.2021.02.007","article-title":"Bioassay-guided isolation of a new cytotoxic ceramide from Cyperus rotundus L","volume":"139","author":"Samra","year":"2021","journal-title":"South Afr. J. Bot."},{"issue":"33","key":"10.1016\/j.heliyon.2021.e07962_bib50","doi-asserted-by":"crossref","first-page":"13990","DOI":"10.1039\/D0NJ02844D","article-title":"Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor","volume":"44","author":"Al-Karmalawy","year":"2020","journal-title":"New J. Chem."},{"issue":"39","key":"10.1016\/j.heliyon.2021.e07962_bib51","doi-asserted-by":"crossref","first-page":"16752","DOI":"10.1039\/D0NJ03611K","article-title":"Molecular docking reveals the potential of Cleome amblyocarpa isolated compounds to inhibit COVID-19 virus main protease","volume":"44","author":"Zaki","year":"2020","journal-title":"New J. Chem."},{"issue":"12","key":"10.1016\/j.heliyon.2021.e07962_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05641","article-title":"Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease","volume":"6","author":"Alnajjar","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2021.e07962_bib53","series-title":"3: Desmond Molecular Dynamics System, DE Shaw Research, New York, NY","author":"Release","year":"2017"},{"issue":"2","key":"10.1016\/j.heliyon.2021.e07962_bib54","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J.\u00a0Chem. Phys."},{"issue":"1","key":"10.1016\/j.heliyon.2021.e07962_bib55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.heliyon.2021.e07962_bib56","series-title":"Desmond\/GPU Performance as of October 2015","author":"Bergdorf","year":"2015"},{"issue":"4","key":"10.1016\/j.heliyon.2021.e07962_bib57","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1063\/1.463940","article-title":"Nos\u00e9\u2013Hoover chains: the canonical ensemble via continuous dynamics","volume":"97","author":"Martyna","year":"1992","journal-title":"J.\u00a0Chem. Phys."},{"issue":"5","key":"10.1016\/j.heliyon.2021.e07962_bib58","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1063\/1.467468","article-title":"Constant pressure molecular dynamics algorithms","volume":"101","author":"Martyna","year":"1994","journal-title":"J.\u00a0Chem. Phys."},{"issue":"4","key":"10.1016\/j.heliyon.2021.e07962_bib59","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot087379","article-title":"Crystal violet assay for determining viability of cultured cells","volume":"2016","author":"Feoktistova","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"issue":"22","key":"10.1016\/j.heliyon.2021.e07962_bib60","first-page":"e00489","article-title":"Coding-complete genome sequences of two SARS-CoV-2 isolates from Egypt","volume":"9","author":"Kandeil","year":"2020","journal-title":"Microbiol. Res. Announ."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402102065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402102065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:49:21Z","timestamp":1773769761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402102065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S240584402102065X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2021.e07962","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2021.e07962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e07962"}}